Amarillo Biosciences is a specialty biopharmaceutical company working in Phase 2 human clinical trials with a well-characterized therapeutic agent, interferon-alpha, in a proprietary low-dose oral formulation.

Our low-dose oral interferon has been shown to have fewer side effects and is less costly than high-dose injectable interferon.

We have license to low-dose oral interferon from Texas A&M University and agreements in place with international partner companies who are pursuing clinical trials globally.

Our management team and corporate partners are working to develop a non-toxic and inexpensive low-dose oral formulation of interferon-alpha for the benefit of patients and physicians worldwide.

Amarillo Biosciences and its partners are pursuing major disease indications, with a focus on  influenza and hepatitis C.